Market Access News | pharmaphorum

News

Are rapid progress and patient engagement mutually exclusive in a COVID-19 world?

Pfizer, BioNTech seek US okay for Omicron BA.4/BA.5 booster

Pfizer and BioNTech have asked the FDA for emergency authorisation of an Omicron-targeted COVID-19 booster vaccine ahead of the planned autumn immunisation campaign in the US.

News

EMA starts review of Cidara's candidiasis therapy rezafungin

The EU regulator has started its review of Cidara Therapeutics' once-weekly antifungal rezafungin, setting up a decision next year as a new option for serious, invasive infections caused by

News

Gilead bags first approval for twice-yearly HIV therapy

The European Commission has become the first regulator worldwide to approved a therapy from Gilead Sciences for people with multidrug-resistant (MDR) HIV infection that only needs to be tak

News

Axsome bounces back as FDA clears depression drug

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was

News

bluebird unveils $2.8m price for gene therapy Zynteglo on FD...

bluebird bio's Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require re

News

Mature Woman Experiencing Hot Flush From Menopause

Astellas files menopause drug fezolinetant in US, setting up...

Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-

Pfizer, BioNTech seek US okay for Omicron BA.4/BA.5 booster

EMA starts review of Cidara's candidiasis therapy rezafungin

Gilead bags first approval for twice-yearly HIV therapy

Axsome bounces back as FDA clears depression drug

bluebird unveils $2.8m price for gene therapy Zynteglo on FD...

Astellas files menopause drug fezolinetant in US, setting up...

Hims & Hers buys Australian digital health firm for $1.15bn

How to meet your physicians where they are online

News

Editor's Picks